Kairos Pharma Ltd. (NYSE American: KAPA) presented interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. The data, disclosed by President and Chief Scientific Officer Neil Bhowmick, showed that in a Phase 2 trial for metastatic castration-resistant prostate cancer (mCRPC), ENV-105 combined with apalutamide achieved a median progression-free survival (PFS) of 17.7 months compared with two months for apalutamide alone (P=0.0008). This statistically significant improvement suggests that targeting CD105, a protein associated with drug resistance and relapse, may restore sensitivity to standard therapies.
The implications are substantial for patients with mCRPC, a condition where resistance to androgen receptor inhibitors like enzalutamide frequently develops. By interrupting CD105/BMP signaling, ENV-105 could delay disease progression and extend the benefit of existing treatments. The trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group. Preclinical research has also indicated that ENV-105 may enhance radiation sensitivity in prostate cancer models, further broadening its potential application.
Bhowmick noted that the findings support the company's hypothesis that targeting CD105 may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies. If confirmed in larger studies, ENV-105 could become a first-in-class agent that addresses a critical unmet need in oncology. Kairos Pharma, based in Los Angeles, California, is utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's approach with ENV-105, an antibody targeting CD105, aims to reverse resistance across multiple cancer types.
For investors, the interim results represent a significant milestone for Kairos Pharma (NYSE American: KAPA). The full press release can be viewed at https://ibn.fm/PIrky, and the latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. The announcement was disseminated through TinyGems, a communications platform focused on innovative small-cap and mid-cap companies, which is part of the Dynamic Brand Portfolio @ IBN. IBN provides wire solutions via InvestorWire and other services to help companies reach a wide audience. The full terms of use and disclaimers are available at https://www.TinyGems.com/Disclaimer.
